2025 brought a wave of initiatives that will shape how we think about service-provider offerings in 2026 and beyond. Many companies expanded their product suites by strengthening AI capabilities—some through acquisitions (e.g., Thermo Fisher–Clario, Siemens–Dotmatics, Tempus AI–Deep 6 AI) and others through strategic partnerships (e.g., Tempus with AstraZeneca and Pathos AI, Guardant-ConcertAI, Lunit-Labcorp).
A major trend for 2025 is the push to develop new products for pharma. Illumina and Ovation.io are doing this by building a large multiomic GLP-1 dataset, while the NIH is working to expand access to organoid resources to reduce reliance on animal models for research and regulatory purposes. Pfizer is tapping into Charles River and Valo’s Logica platform in its latest Flagship Pioneering collaboration to support AI-driven drug design. Meanwhile, Platomics is focusing on the regulatory landscape, partnering with Agilent and Sophia Genetics to streamline IVDR compliance for labs developing NGS tests.
Among the hundreds of partnerships and deals in the pharma services space in 2025, here are more details on a select few that stood out to us:
Thermo Fisher Scientific Adds Clario in ~$9B Deal
Thermo Fisher Scientific agreed to acquire Clario, a provider of clinical trial technology and data solutions, in a transaction valued at about $9 billion. The agreement also includes a $125 million payment in 2027 and potential additional payouts of up to $400 million across 2026 and 2027.
Clario’s platform for collecting and managing clinical trial data supported roughly 70% of FDA drug approvals over the past decade. In its Q3 2025 results, Clario reported 5% year-over-year sales growth, and Thermo expects that growth to accelerate into the high single digits after the acquisition.
The deal is expected to close in mid-2026 and strengthen Thermo’s digital and AI capabilities.
Siemens Acquires Dotmatics for ~$5B
Siemens acquired R&D software developer Dotmatics from Insight Partners in a $5.1 billion deal, with Siemens Healthineers expected to take a leading role in the business. The acquisition strengthens Siemens’ position in life sciences software, particularly by expanding its AI capabilities and advancing the use of digital twin technologies.
Siemens anticipates mid-term annual revenues of nearly $100 million from the business, with longer-term potential to exceed $500 million per year. The deal is expected to close in the first half of 2026.
Tempus AI acquired Deep 6 AI, a company that uses AI to match patients to clinical trials by mining EMR data and other structured information (such as demographics, pathology reports, and lab results) across academic medical centers, NCI cancer centers, and community oncology sites.
Deep 6’s integration infrastructure will strengthen Tempus’ ability to connect patients and clinicians with trial opportunities and to support research efforts. This is especially relevant for Tempus’ product Next, which delivers insights from longitudinal patient data and supports oncology and cardiology use cases. Tempus also offers Time, which helps accelerate site activation and patient enrollment for precision medicine trials.
Tempus has Signed a Multiyear, $200M Deal to Accelerate Drug Development
Tempus AI will receive $200 million in licensing fees and model-development costs from AstraZeneca and Pathos AI to build a multimodal oncology model. The model will integrate biological and clinical insights to support drug discovery, target identification, and other research efforts, and each partner will be able to apply it to their own programs.
AstraZeneca and Tempus have collaborated since 2021 on a multiomics dataset for biomarker discovery using SCLC and NSCLC clinical trial data. The new agreement expands on that work to create a more foundational model, leveraging Tempus’ extensive datasets, including over 8 million de-identified patient records, more than 2 million imaging records, and over 1 million records with integrated clinical and genomic data.
Guardant Health and ConcertAI Partner to Expand Real World Data Offerings
Guardant Health and ConcertAI formed a collaboration to give pharma companies access to a database that integrates EMR data with genomic and epigenomic tumor-profiling insights. ConcertAI’s repository of more than 5 million clinical records will add clinical context to Guardant’s molecular data, enabling pharma to design better clinical trials, identify new therapeutic opportunities, and assess treatment effectiveness.
The combined dataset will include methylation data, genomic data, and other molecular profiling information (e.g., MRD and recurrence insights) from Guardant’s suite of products.
Lunit and Labcorp Collaborate to Expand Innovation in Digital Pathology and AI Oncology Research
Lunit and Labcorp entered a strategic collaboration to apply AI-powered spatial profiling to digital pathology. The partnership aims to analyze tumor microenvironments more effectively, with initial insights focsed on identifying immune phenotypes in NSCLC patients with MET alterations, including exon 14 skipping mutations. This collaboration seeks to accelerate biomarker discovery and improve precision oncology treatment strategies.
NIH to Use $80+M for Organoid Center and Pivot Away from Animal Testing
The National Institutes of Health awarded $87 million in contracts over three years to launch the Standardized Organoid Modeling (SOM) Center at the Frederick National Laboratory for Cancer Research, aimed at developing standardized lab-grown tissue models of human organs to reduce reliance on animal testing in preclinical drug testing.
The center will use AI, machine learning, and advanced robotics to create reproducible organoid models initially focused on the liver, lung, heart, and intestine, serving as a resource for scientists, regulatory bodies like the FDA, clinicians, and industry researchers worldwide.
Illumina and Ovation.io to generate GLP-1 Dataset
Illumina and Ovation.io announced plans to develop a clinical multiomic dataset from 25,000 patients treated with GLP-1 agonists. The dataset will integrate phenotypic, genomic, and proteomic data to help pharma better understand GLP-1 efficacy and identify new biomarkers or drug targets for patients who do not respond to these therapies.
In addition to 25,000 whole genomes, the dataset will include protein-expression profiles from 5,000 samples. Ovation.io will also contribute 1.7 million biobanked samples linked to longitudinal phenotypic data, further expanding the depth and utility of the resource.
Platomics enters Partnerships to Automate IVDR Compliance Documentation
Platomics, a regulatory compliance software provider, partnered with Agilent Technologies to offer laboratory documentation support for NGS tests developed under the EU’s IVDR. Agilent customers developing NGS assays can use Platomics’ PlatoX platform to generate the required IVDR documentation.
Platomics also partnered with Sophia Genetics to streamline IVDR compliance for clinical labs using Sophia’s NGS products. Sophia customers can use PlatoX, which will include registered Sophia products so that users can access the necessary data to complete technical documentation for their tests.
Both partnerships aim to automate IVDR standardization and support end-to-end validation and documentation for clinical labs.
Pfizer-Flagship to Tap Logica Platform
Pfizer and Flagship Pioneering are in a multibillion-dollar, 10-program partnership, and one of their new initiatives will focus on autoimmune diseases. Discovery will be led by Pioneering Medicines, which previously collaborated with Charles River Laboratories and Valo Health on the Logica molecule-design platform.
Logica, which is powered by Valo and Charles River, is a promising computational drug-design system and has already produced its first drug candidate this year for lupus and other autoimmune conditions. Pfizer and Flagship plan to leverage this platform to identify new candidates for autoimmune disease programs.
.png)
